Brain Monitoring Devices Market Research: Evolving Technology and Busines Outlook to 2024 | Factors

Read the 130-page research report with TOC on "Neurodiagnostic and Monitoring Devices Market in the US Analysis Report by Product (ICP monitoring devices, EEG devices, EMG devices, and Others), and Segment Forecasts, 2020-2024".

The market is driven by the increasing incidence and prevalence of neurological conditions. In addition, the paradigm shift toward hybrid brain-computer interface is anticipated to further boost the growth of the neurodiagnostic and monitoring devices market in the US.

Brain Monitoring Devices Market evolving technology and busines outlook TO 2024

Download File: https://gohhs.com/2vAod7

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

NEW YORK, May 12, 2022 /PRNewswire/ -- The global non-invasive intracranial pressure monitoring devices market size is expected to grow by USD 125.89 million from 2021 to 2026 at a CAGR of 6.02% as per the latest market report by Technavio. 41% of the market's growth will originate from North America during the forecast period. The US is the key market for the non-invasive intracranial pressure monitoring devices market in North America. Market growth in this region will be slower than the growth of the market in Asia. The presence of global key vendors will facilitate the non-invasive intracranial pressure monitoring devices market growth in North America over the forecast period.

Read the 120-page report with TOC on "Non-Invasive Intracranial Pressure Monitoring Devices Market Analysis Report by Application (Traumatic brain injury, Intracerebral hemorrhage, Subarachnoid hemorrhage, Meningitis, and Others) and Geography (North America, Europe, Asia, and Rest of World (ROW)), and the Segment Forecasts,2022-2026". Gain competitive intelligence about market leaders. Track key industry opportunities, trends, and threats. Information on marketing, brand, strategy and market development, sales, and supply functions - -invasive-intracranial-pressure-monitoring-devices-market-industry-analysis

The non-invasive intracranial pressure monitoring devices market is concentrated and the vendors are deploying growth strategies such as investing in the development of customized solutions to compete in the market. The non-invasive intracranial pressure monitoring devices market report also offers information on several market vendors, including Compumedics Ltd., Integra LifeSciences Corp., Johnson and Johnson, Medtronic Plc, Natus Medical Inc., Nihon Kohden Corp., RAUMEDIC AG, Sophysa, and Spiegelberg GmbH and Co. KG among others.

The growing awareness of non-invasive ICP monitoring devices is one of the key drivers supporting the non-invasive intracranial pressure monitoring devices market growth. For instance, in North America, the United States Brain Injury Alliance, Brain Injury Association of Canada, and Brain Injury Association of America are a few organizations that are working toward raising awareness about the prevention and management of brain injuries. These organizations also promote the use of non-invasive ICP monitoring devices. The presence of such organizations and associations helps in increasing awareness regarding brain injuries and provides support to hospitals and medical centers. These efforts are expected to enhance the growth of the global non-invasive ICP monitoring devices market during the forecast period.

However, the availability and use of invasive ICP monitoring devices is the factor hindering the non-invasive intracranial pressure monitoring devices market growth. Advances in technology have expanded the use of invasive ICP monitoring devices in conjunction with other medical devices. For instance, Integra LifeSciences offers Camino Flex Ventricular Catheter in conjunction with the magnetic resonance imaging (MRI) scan under the 1.5 and 3 Tesla devices. Camino Flex ventricular catheter is used for ICP monitoring as well as for the management of CSF. All these developments have resulted in the increased adoption of invasive ICP monitoring devices. Thus, the availability of invasive ICP monitoring devices as a substitute will pose a threat to the market vendors. Such market challenges can negatively impact the growth of the global non-invasive ICP monitoring devices market during the forecast period.

About TechnavioTechnavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

Based on end-use, sleep tech devices are classified into specialty clinics, direct-to-consumer, hospitals and others. The hospital segment garnered over USD 2 billion market size in 2021 and is expected to grow substantially over the forthcoming years. Hospital segment accounts for sales of sleep tech devices through intervention of physicians working at hospital premises. The devices are recommended to patients for treatment and monitoring of sleep related health issues will augment the segmental as well as healthcare cybersecurity market growth.

North America sleep tech devices business captured over 42% market share in 2021 and is poised to grow substantially through 2030 due to and presence of well-developed healthcare facilities in this region and increasing launch of sleep tech devices.

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2013 to 2024. For the purpose of this study, Grand View Research has segmented the global next generation cancer diagnostics market report on the basis of technology, applications, function, cancer type, and region:

The Microsoft Cloud is the most comprehensive and trusted cloud, providing the best integration across the technology stack while offering openness, improving time to value, reducing costs, and increasing agility. Being a global-scale cloud, Azure uniquely offers hybrid consistency, developer productivity, AI capabilities, and trusted security and compliance. We see more emerging use cases and needs for compute and security at the edge and are accelerating our innovation across the spectrum of intelligent edge devices, from IoT sensors to gateway devices and edge hardware to build, manage, and secure edge workloads. With Azure Stack, organizations can extend Azure into their own datacenters to create a consistent stack across the public cloud and the intelligent edge. Our hybrid infrastructure consistency spans security, compliance, identity, and management, helping to support the real-world needs and evolving regulatory requirements of commercial customers and enterprises. Azure Arc simplifies governance and management by delivering a consistent multi-cloud and on-premises management platform. Security, compliance, identity, and management underlie our entire tech stack. We offer integrated, end-to-end capabilities to protect people and organizations. In April 2021, we entered into a definitive agreement to acquire Nuance Communications, Inc., a cloud and AI software provider with healthcare and enterprise AI experience. The acquisition will build on our industry-specific cloud offerings.

Our success is based on our ability to create new and compelling products, services, and experiences for our users, to initiate and embrace disruptive technology trends, to enter new geographic and product markets, and to drive broad adoption of our products and services. We invest in a range of emerging technology trends and breakthroughs that we believe offer significant opportunities to deliver value to our customers and growth for the Company. Based on our assessment of key technology trends, we maintain our long-term commitment to research and development across a wide spectrum of technologies, tools, and platforms spanning digital work and life experiences, cloud computing, AI, devices, and operating systems.

We generate revenue by offering a wide range of cloud-based and other services to people and businesses; licensing and supporting an array of software products; designing, manufacturing, and selling devices; and delivering relevant online advertising to a global audience. Our most significant expenses are related to compensating employees; designing, manufacturing, marketing, and selling our products and services; datacenter costs in support of our cloud-based services; and income taxes.

We will continue to invest in sales, marketing, product support infrastructure, and existing and advanced areas of technology, as well as continue making acquisitions that align with our business strategy. Additions to property and equipment will continue, including new facilities, datacenters, and computer systems for research and development, sales and marketing, support, and administrative staff. We expect capital expenditures to increase in coming years to support growth in our cloud offerings. We have operating and finance leases for datacenters, corporate offices, research and development facilities, Microsoft Experience Centers, and certain equipment. We have not engaged in any related party transactions or arrangements with unconsolidated entities or other persons that are reasonably likely to materially affect liquidity or the availability of capital resources.

We review debt investments quarterly for credit losses and impairment. If the cost of an investment exceeds its fair value, we evaluate, among other factors, general market conditions, credit quality of debt instrument issuers, and the extent to which the fair value is less than cost. This determination requires significant judgment. In making this judgment, we employ a systematic methodology that considers available quantitative and qualitative evidence in evaluating potential impairment of our investments. In addition, we consider specific adverse conditions related to the financial health of, and business outlook for, the investee. If we have plans to sell the security or it is more likely than not that we will be required to sell the security before recovery, then a decline in fair value below cost is recorded as an impairment charge in other income (expense), net and a new cost basis in the investment is established. If market, industry, and/or investee conditions deteriorate, we may incur future impairments. 2ff7e9595c